MoneyWorks4Me

Sanjivani Paranteral - Quaterly Results

08 Aug 2022 Evaluate
The company witnessed a 22.70% growth in the revenue at Rs. 99.17 millions for the quarter ended June 2022 as compared to Rs. 80.82 millions during the year-ago period.The Net Profit of the company vaulted to 186.15% to Rs. 17.97  millions from Rs. 6.28 millions in the previous quarter.Operating profit for the quarter ended June 2022 rose to 22.74 millions as compared to 8.35 millions of corresponding quarter ended June 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 99.17 80.82 22.70 99.17 80.82 22.70 306.13 251.00 21.96
Other Income 1.17 0.72 62.50 1.17 0.72 62.50 2.43 2.58 -5.81
PBIDT 22.74 8.35 172.34 22.74 8.35 172.34 59.69 23.99 148.81
Interest 0.74 0.31 138.71 0.74 0.31 138.71 2.13 1.26 69.05
PBDT 22.00 8.04 173.63 22.00 8.04 173.63 57.56 22.73 153.23
Depreciation 2.17 1.76 23.30 2.17 1.76 23.30 8.77 8.60 1.98
PBT 19.83 6.28 215.76 19.83 6.28 215.76 48.79 14.13 245.29
TAX 1.86 0.00 0.00 1.86 0.00 0.00 0.32 -0.07 -557.14
Deferred Tax -0.64 0.00 0.00 -0.64 0.00 0.00 0.32 -0.07 -557.14
PAT 17.97 6.28 186.15 17.97 6.28 186.15 48.47 14.20 241.34
Equity 99.98 84.98 17.65 99.98 84.98 17.65 99.98 84.98 17.65
PBIDTM(%) 22.93 10.33 121.94 22.93 10.33 121.94 19.50 9.56 104.00
Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..